| scholarly article | Q13442814 |
| P2093 | author name string | Lesley Taylor | |
| Barry Gidal | |||
| Bola Tayo | |||
| Gilmour Morrison | |||
| Graham Blakey | |||
| P2860 | cites work | Absorption-Enhancing Effects of Bile Salts | Q26798510 |
| Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review | Q27005619 | ||
| Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review | Q28300877 | ||
| Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. | Q33636763 | ||
| Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome | Q34557114 | ||
| Safety and side effects of cannabidiol, a Cannabis sativa constituent | Q34634008 | ||
| Molecular Targets of Cannabidiol in Neurological Disorders | Q36157649 | ||
| Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses | Q36729800 | ||
| Cannabinoids and Cytochrome P450 Interactions. | Q38664463 | ||
| The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate | Q39156431 | ||
| Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial | Q40151883 | ||
| Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids | Q41340447 | ||
| Interactions between cannabidiol and commonly used antiepileptic drugs. | Q48283873 | ||
| Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial | Q50109024 | ||
| Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. | Q51438384 | ||
| Antipsychotic effect of cannabidiol. | Q51593664 | ||
| Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. | Q52655447 | ||
| Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. | Q53835626 | ||
| Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome | Q62868130 | ||
| Effective half-life in clinical pharmacology | Q70789811 | ||
| Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes | Q84445086 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| cannabinoids | Q422936 | ||
| placebo | Q269829 | ||
| pharmacokinetics | Q323936 | ||
| cannabidiol | Q422917 | ||
| P304 | page(s) | 1053-1067 | |
| P577 | publication date | 2018-10-30 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects | |
| P478 | volume | 32 |
| Q89936596 | 30 years of second-generation antiseizure medications: impact and future perspectives |
| Q64253834 | A Novel Standardized L. Extract and Its Constituent Cannabidiol Inhibit Human Polymorphonuclear Leukocyte Functions |
| Q92676487 | A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment |
| Q91805689 | A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects |
| Q89506050 | A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects |
| Q89611766 | Abrupt withdrawal of cannabidiol (CBD): A randomized trial |
| Q91731937 | Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials |
| Q90598976 | As CBD skyrockets in popularity, scientists scramble to understand how it's metabolized |
| Q90248051 | Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects |
| Q91962253 | Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms |
| Q100458340 | Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase 1 Clinical Trial |
| Q97428443 | Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research |
| Q98181416 | Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial |
| Q89531275 | Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand |
| Q89907362 | Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects |
| Q99711797 | Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products |
| Q64075416 | Medicinal use of cannabis based products and cannabinoids |
| Q90737999 | Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder |
| Q91721752 | Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy |
| Q90248156 | Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders |
| Q91804466 | Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study |
| Q64229781 | The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder |
| Q98507441 | The Essential Medicinal Chemistry of Cannabidiol (CBD) |
| Q91762308 | The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids |
| Q98165843 | The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol |
| Q92878674 | The nephrologist's guide to cannabis and cannabinoids |
Search more.